Rayno Biopharmaceutical Stocks: Amgen (AMGN) Beats

Amgen stock was up 1.5 % yesterday, and over 2% after hours to $172. Total Q1 revenues were up 11% to $5B compared to prior quarter in 2014 and EPS increased by 33% to $2.48. Free cash flow was $1.2B. Earnings guidance were raised but bio similars are looming in 2016.Amgen was recommended on 2/2/09 at a price of $55. The stock is up 46% over one year.

The Rayno Large Cap Biopharma Portfolio is up 16% YTD and includes AMGN, ALXN, BIIB, GILD, REGN, and RHHBY.

Rayno Tools and Diagnostic Stocks: Illumina (ILMN) Beats

Illumina stock was up 3% yesterday, and over 4% after hours to $206. Total Q1 revenues were $529M or $0.92 per diluted share up 28% compared to prior quarter in 2014 and GAAP net income was $137M compared to $60M in 2014 Q1. Fee cash flow was $30M for Q1. Illumina was recommended on 2/2/09 at a price of $29 and the stock is up 47% over one year.

We will review our Diagnostics and Tools portfolio after all Q1 earnings are in. Stocks in the Rayno universe to watch are ABAX, HOLX, QGEN, and TMO.

Healthcare and biotech stocks came back yesterday although speculative stocks were mixed. The IBB was up 1.83%. Rayno Mid Caps were strong lead by Vertex (VRTX) on usual M&A talk. Somebody is expecting big things from Incyte (INCY) up yesterday over 3% and up 49% YTD.

Risk remains on.